Company News
Oruka Therapeutics Shares Surge 45% on Psoriasis Trial
Oruka Therapeutics shares jumped 45% after reporting positive Phase 2a EVERLAST‑A trial results for psoriasis drug ORKA‑001.
Primary endpoint met with 63.5% of patients achieving PASI 100 and IGA 0 at
